Display Settings:

Format

Send to:

Choose Destination
    Am J Pathol. 2002 Dec;161(6):1991-6.

    Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.

    Source

    L235 Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA. mrijn@stanford.edu

    Erratum in

    • Am J Pathol. 2003 Jul;163(1):377.

    Abstract

    While several prognostic factors have been identified in breast carcinoma, the clinical outcome remains hard to predict for individual patients. Better predictive markers are needed to help guide difficult treatment decisions. In a previous study of 78 breast carcinoma specimens, we noted an association between poor clinical outcome and the expression of cytokeratin 17 and/or cytokeratin 5 mRNAs. Here we describe the results of immunohistochemistry studies using monoclonal antibodies against these markers to analyze more than 600 paraffin-embedded breast tumors in tissue microarrays. We found that expression of cytokeratin 17 and/or cytokeratin 5/6 in tumor cells was associated with a poor clinical outcome. Moreover, multivariate analysis showed that in node-negative breast carcinoma, expression of these cytokeratins was a prognostic factor independent of tumor size and tumor grade.

    PMID:
    12466114
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC1850928
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 2.
    Figure 1.

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk